MYMD vs. CDIO, BMRA, VRAX, NAVB, FREQ, OCX, ICCC, ALGS, DRRX, and IDXX
Should you be buying MyMD Pharmaceuticals stock or one of its competitors? The main competitors of MyMD Pharmaceuticals include Cardio Diagnostics (CDIO), Biomerica (BMRA), Virax Biolabs Group (VRAX), Navidea Biopharmaceuticals (NAVB), Frequency Therapeutics (FREQ), OncoCyte (OCX), ImmuCell (ICCC), Aligos Therapeutics (ALGS), DURECT (DRRX), and IDEXX Laboratories (IDXX). These companies are all part of the "medical" sector.
Cardio Diagnostics (NASDAQ:CDIO) and MyMD Pharmaceuticals (NASDAQ:MYMD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation, risk and community ranking.
Cardio Diagnostics presently has a consensus price target of $2.00, suggesting a potential upside of 327.17%. Given MyMD Pharmaceuticals' higher probable upside, analysts clearly believe Cardio Diagnostics is more favorable than MyMD Pharmaceuticals.
Cardio Diagnostics has a beta of 4.95, meaning that its share price is 395% more volatile than the S&P 500. Comparatively, MyMD Pharmaceuticals has a beta of 2.15, meaning that its share price is 115% more volatile than the S&P 500.
MyMD Pharmaceuticals has lower revenue, but higher earnings than Cardio Diagnostics.
Cardio Diagnostics received 3 more outperform votes than MyMD Pharmaceuticals when rated by MarketBeat users.
8.1% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 9.6% of MyMD Pharmaceuticals shares are owned by institutional investors. 30.0% of Cardio Diagnostics shares are owned by company insiders. Comparatively, 2.1% of MyMD Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Cardio Diagnostics had 1 more articles in the media than MyMD Pharmaceuticals. MarketBeat recorded 3 mentions for Cardio Diagnostics and 2 mentions for MyMD Pharmaceuticals. MyMD Pharmaceuticals' average media sentiment score of 0.96 beat Cardio Diagnostics' score of 0.43 indicating that Cardio Diagnostics is being referred to more favorably in the media.
MyMD Pharmaceuticals has a net margin of 0.00% compared to MyMD Pharmaceuticals' net margin of -34,911.87%. Cardio Diagnostics' return on equity of -179.05% beat MyMD Pharmaceuticals' return on equity.
Summary
Cardio Diagnostics beats MyMD Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
Get MyMD Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MYMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MYMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MyMD Pharmaceuticals Competitors List
Related Companies and Tools
Free MYMD Stock Alerts